Health
Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273) – Business Wire
Moderna announces publication of interim results from older adult age cohorts in Phase 1 study of its mRNA vaccine in NEJM.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of the second interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, inThe New England Journal of Medicine. This interim analysis evaluated a two-dose vaccination schedule of mRNA-1273 given 28 days apart…
-
Business21 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News21 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General15 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News18 hours agoTips to improve engagement – Proctor